Relapsed Leukemia

Patients with post-transplant relapsed B-cell acute lymphoblastic leukemia who received chimeric antigen receptor T-cell therapy had superior outcomes compared with alternative approaches, study results showed.

In this video, Aaron T. Gerds, MD, from the Cleveland Clinic Taussig Cancer Institute, discusses a new IDH inhibitor, olutasidenib, which was found to be well tolerated in patients with relapsed or refractory acute myeloid leukemia.